Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 2
2017 3
2018 3
2019 4
2020 4
2021 5
2022 2
2023 1
2024 9
2025 12
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.
Kim D, Shim J, Choi EK, Oh IY, Kim J, Lee YS, Park J, Ko JS, Park KM, Sung JH, Park HW, Park HS, Kim JY, Kang KW, Kim D, Park JK, Kim DH, Kim JB, Yu HT, Kim TH, Uhm JS, Pak HN, Joung B; ALONE-AF Investigators. Kim D, et al. JAMA. 2025 Oct 14;334(14):1246-1254. doi: 10.1001/jama.2025.14679. JAMA. 2025. PMID: 40886309 Free PMC article. Clinical Trial.
Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, Choi EK, Lee JH, Kwon CH, Park GM, Choi HO, Park KH, Park KM, Hwang J, Yoo KD, Cho YR, Kim JH, Hwang KW, Jin ES, Kwon O, Kim KH, Park SJ, Park DW, Nam GB; EPIC-CAD Investigators. Cho MS, et al. N Engl J Med. 2024 Dec 5;391(22):2075-2086. doi: 10.1056/NEJMoa2407362. Epub 2024 Sep 1. N Engl J Med. 2024. PMID: 39225258 Clinical Trial.
CONCLUSIONS: In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinic …
CONCLUSIONS: In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composit …
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
Kwon CH, Kim YJ, Kim MJ, Cha MJ, Cho MS, Nam GB, Choi KJ, Kim J. Kwon CH, et al. Among authors: cho ms. Am J Cardiol. 2022 Sep 1;178:35-42. doi: 10.1016/j.amjcard.2022.05.017. Epub 2022 Jul 7. Am J Cardiol. 2022. PMID: 35810007
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adver …
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with ty …
Atrial fibrillation burden and symptom, quality of life, and healthcare resource utilization after cryoballoon ablation in persistent atrial fibrillation.
Yeo M, Lee SR, Choi J, Lee KY, Ahn HJ, Kwon S, Lee JH, Cho Y, Oh IY, Lim HE, Cho MS, Nam GB, Oh S, On YK, Choi EK. Yeo M, et al. Among authors: cho ms. Europace. 2025 Aug 4;27(8):euaf150. doi: 10.1093/europace/euaf150. Europace. 2025. PMID: 40879123 Free PMC article.
AF-related HCRU was defined as rhythm control interventions after the 90-day blanking period and cardiovascular-related hospitalizations or emergency room visits. Among 130 patients (mean baseline AF burden 77 34%), AF burden significantly decreased post-CBA, with 50.0% …
AF-related HCRU was defined as rhythm control interventions after the 90-day blanking period and cardiovascular-related hospitalizati …
Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation.
Shoji S, Gouda P, Falvey CA, Barnhart H, Cyr DD, Mentz RJ, Piccini JP, Patel MR, Jones WS, Kittipibul V, Cho MS, Tannu M, Sato S, Nicolau A, Palazzolo M, Wallentin L, Eikelboom J, Hong H, Giugliano RP, Reed SD, Granger CB. Shoji S, et al. Among authors: cho ms. NEJM Evid. 2026 Jun;5(6):EVIDoa2500323. doi: 10.1056/EVIDoa2500323. Epub 2026 May 26. NEJM Evid. 2026. PMID: 42187550
Comparison of Extended Cryoballoon, Standard Cryoballoon, and Radiofrequency Catheter Ablation in Patients With Persistent AF.
Cho MS, Lee JH, Oh IY, Lee JB, Kim M, Choi KJ, Cho Y, Nam GB; EXCAPE-AF Investigators. Cho MS, et al. JACC Clin Electrophysiol. 2025 Dec;11(12):2701-2711. doi: 10.1016/j.jacep.2025.08.003. Epub 2025 Sep 1. JACC Clin Electrophysiol. 2025. PMID: 40888774 Clinical Trial.
No significant differences were observed in the rates of direct current cardioversion (9.6% vs 10.2% vs 4.2%; P = 0.236) or cardiovascular hospitalization (3.2% vs 0% vs 2.1%; P = 0.170). The incidence of major adverse events was also comparable among the groups (1.0% in a …
No significant differences were observed in the rates of direct current cardioversion (9.6% vs 10.2% vs 4.2%; P = 0.236) or cardiovascula …
Long-Term Antithrombotic Therapy in Patients With Atrial Fibrillation and Prior PCI: Insights From EPIC-CAD Trial.
Wee SB, Kang DY, Cho MS, Kim MJ, Ahn JM, Park HS, An SY, Seo KW, Lee SH, Oh YS, Lee CH, Choi EK, Lee JH, Kwon CH, Park GM, Choi HO, Park KH, Park KM, Hwang J, Yoo KD, Cho YR, Kim JH, Hwang KW, Jin ES, Kwon O, Kim KH, Park SJ, Nam GB, Park DW; EPIC-CAD Investigators. Wee SB, et al. Among authors: cho ms. J Am Coll Cardiol. 2025 Sep 23;86(12):940-943. doi: 10.1016/j.jacc.2025.07.035. Epub 2025 Aug 27. J Am Coll Cardiol. 2025. PMID: 40864010 No abstract available.
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
Cho MS, Kang DY, Lee JB, Oh YS, Lee CH, Choi EK, Lee JH, Kwon CH, Park GM, Choi HO, Park KH, Park KM, Hwang J, Yoo KD, Cho YR, Kim JH, Hwang KW, Jin ES, Kwon O, Kim KH, Park DW, Nam GB; on the behalf of the EPIC-CAD Investigators. Cho MS, et al. Heart. 2026 Mar 12;112(7):391-398. doi: 10.1136/heartjnl-2025-326646. Heart. 2026. PMID: 40930594 Clinical Trial.
47 results